EUNew treatments and approvals
Oral rilzabrutinib approved in the EU for adults with ITP who did not respond to other treatments
A decision by a medicines regulator (FDA, European Commission, etc.). The regulator has reviewed the clinical studies behind the drug. For accelerated or conditional approvals, the lasting benefit is still being confirmed.
The European Commission approved rilzabrutinib on December 22, 2025. The drug is for adult ITP patients who have not responded to other treatments. The main trial included 202 adults. After 24 weeks, the platelet count stayed at an adequate level in 23% of those on the drug. In those on placebo, this rate was zero.
What does it mean for patients and families?
This approval applies within the European Union. Access in Türkiye depends on TİTCK (Turkish Medicines and Medical Devices Agency) and SGK (Social Security Institution) processes. Treatment decisions are made with your doctor.
Source
Avrupa İlaç Ajansı (EMA) · source page
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Immune thrombocytopenia (ITP)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.